{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:58:45Z","timestamp":1779260325766,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2022557"],"award-info":[{"award-number":["APP2022557"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP 1155066"],"award-info":[{"award-number":["APP 1155066"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1173163"],"award-info":[{"award-number":["APP1173163"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024744","name":"Snow Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024744","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023692","name":"Doherty Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jinf.2024.106346","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:00:54Z","timestamp":1731686454000},"page":"106346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-&lt;50 and 50-&lt;70 years old"],"prefix":"10.1016","volume":"89","author":[{"given":"C.","family":"McLeod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dymock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KL","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Plebanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HS","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MJ","family":"Estcourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Wadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MC","family":"Tjiam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CC","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FL","family":"Mordant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Brizuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SN","family":"Faust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RB","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mckenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JA","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TL","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PC","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2024.106346_bib1","unstructured":"Australian Institute of Health and Welfare. The impact of a new disease: COVID-19 from 2020, 2021 and into 2022, 2022, Department of Health, 2022, accessible at: aihw.gov.au\/getmedia\/c017fa79-be4b-4ad5-bbf3-2878ed0995e5\/aihw-aus-240_chapter_1.pdf.aspx."},{"issue":"31","key":"10.1016\/j.jinf.2024.106346_bib2","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1016\/j.vaccine.2023.06.005","article-title":"Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021\u2013January 2022","volume":"41","author":"de Gier","year":"2023","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.jinf.2024.106346_bib3","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.jinf.2024.106346_bib4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106346_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13063-023-07225-z","article-title":"Core Protocol for the adaptive Platform Trial in COVID-19 vaccine priming and BOOsting (PICOBOO)","volume":"24","author":"McLeod","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.jinf.2024.106346_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-024-08343-y","article-title":"Statistical considerations for the Platform Trial in COVID-19 vaccine priming and boosting","volume":"25","author":"Dymock","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.jinf.2024.106346_bib7","unstructured":"REDcap Consortium. Research Electronic Data Capture (REDCap) Version 14.3.11. Vanderbilt University, 2024, accessible at: https:\/\/projectredcap.org\/."},{"key":"10.1016\/j.jinf.2024.106346_bib8","unstructured":"ICH expert working group, Addenum on estimands and sensitivity analysis in clincial trials to the guideline on statistical principles for clinical trials E9(R1), International council for harmonisation of technical requirements for pharmaceutical products for human use, 2019, accessible at:\u3008https:\/\/www.fda.gov\/media\/108698\/download\u3009."},{"key":"10.1016\/j.jinf.2024.106346_bib9","unstructured":"Stan Development Team, Stan Modeling Landuage Users Guide and Reference Manual 2.34.; 2024, accessible at https:\/\/mc-stan.org."},{"key":"10.1016\/j.jinf.2024.106346_bib10","unstructured":"J. Gabry, R. Cesnovar, A. Johnson, cmdstanr: R Interface to 'CmdStan', 2022, accessible at: https:\/\/mc-stan.org\/cmstandr."},{"key":"10.1016\/j.jinf.2024.106346_bib11","unstructured":"R Core Team, A language and environment for statistical computing, R foundation for statistical computing; 2022, accessible at: https:\/\/www.R-project.org\/."},{"issue":"9","key":"10.1016\/j.jinf.2024.106346_bib12","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/s41591-023-02503-4","article-title":"Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial","volume":"29","author":"Branche","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jinf.2024.106346_bib13","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","volume":"22","author":"Munro","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2024.106346_bib14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s43587-021-00114-7","article-title":"SARS-CoV-2, COVID-19 and the aging immune system","volume":"1","author":"Bartleson","year":"2021","journal-title":"Nat Aging"},{"issue":"6","key":"10.1016\/j.jinf.2024.106346_bib15","article-title":"The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old","volume":"89","author":"McLeod","year":"2024","journal-title":"J Infect"},{"issue":"11","key":"10.1016\/j.jinf.2024.106346_bib16","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3390\/vaccines10111904","article-title":"Correlation of binding and neutralizing antibodies against SARS-CoV-2 Omicron variant in infection-na\u00efve and convalescent BNT162b2 recipients","volume":"10","author":"Fu","year":"2022","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.jinf.2024.106346_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33864-y","article-title":"Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources","volume":"13","author":"Sullivan","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jinf.2024.106346_bib18","series-title":"XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants","author":"Wang","year":"2023"},{"issue":"10318","key":"10.1016\/j.jinf.2024.106346_bib19","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jinf.2024.106346_bib20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14760584.2022.2098719","article-title":"Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis","volume":"21","author":"Sutton","year":"2022","journal-title":"Expert Rev Vaccin"},{"issue":"16","key":"10.1016\/j.jinf.2024.106346_bib21","doi-asserted-by":"crossref","first-page":"10400","DOI":"10.3390\/ijerph191610400","article-title":"Public health management of the COVID-19 pandemic in Australia: the role of the Morrison government","volume":"19","author":"Duckett","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"10.1016\/j.jinf.2024.106346_bib22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1473-3099(22)00376-0","article-title":"FIND documents dramatic reduction in COVID-19 testing","volume":"22","author":"Usher","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2024.106346_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.csda.2019.106901","article-title":"Borrowing strength and borrowing index for Bayesian hierarchical models","volume":"144","author":"Xu","year":"2020","journal-title":"Comput Stat Data Anal"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324002810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324002810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:30:56Z","timestamp":1762248656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324002810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0163445324002810"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106346","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106346"}}